Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
NeoImmuneTech
Alterome Therapeutics, Inc.
National Cancer Institute (NCI)
BeOne Medicines
Genmab
Eli Lilly and Company
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Genmab
Accent Therapeutics
Seagen Inc.
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
A2 Biotherapeutics Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
NiKang Therapeutics, Inc.
Institute of Cancer Research, United Kingdom
City of Hope Medical Center
Institut Curie
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
Eli Lilly and Company
Ocellaris Pharma, Inc.
Seagen Inc.
Elephas
Fusion Pharmaceuticals Inc.
Apollo Therapeutics Ltd
Innate Pharma
Novartis
OncoNano Medicine, Inc.
I-Mab Biopharma US Limited
NeoTX Therapeutics Ltd.
M.D. Anderson Cancer Center
Avenzo Therapeutics, Inc.
Merck Sharp & Dohme LLC
BicycleTx Limited
Bolt Biotherapeutics, Inc.
Pfizer